Joel Chamberlain
Research Associate Professor
Medical Genetics

Faculty Information

Biography

Joel Chamberlain moved to the University of Washington in 2001 from the University of Michigan Medical School where she had completed graduate training in Cell and Molecular Biology in the laboratory of Dr. David Engelke (Biological Chemistry).  Her postdoctoral training at UW in the laboratory of Dr. David Russell (Hematology) culminated in a first authored manuscript in Science detailing gene targeting using adeno-associated viral vectors (AAV) for dominant bone disease therapy development.  Gene targeting was developed to eliminate the mutant collagen gene in mesenchymal stem cells from individuals with the Brittle Bone disease osteogenesis imperfecta.  As a faculty member in the Division of Medical Genetics in the Department of Medicine at UW Joel Chamberlain has developed a gene therapy research program aimed at treating dominantly inherited muscle disorders.  Her approach is based on RNA interference methods using AAV-mediated muscle delivery for the most common adult muscular dystrophies, myotonic dystrophy (DM) and facioscapulohumeral dystrophy (FSHD).  She is also studying FSHD in both patient muscle biopsies and a tunable mouse model developed in her laboratory.

Education & Training: 
B.S.
Tulane University
1987
Ph.D., Cellular and Molecular Biology
University of Michigan
1997
Postdoctoral Fellowship in Rheumatology
University of Michigan
2000
Postdoctoral Fellowship in Hematology
University of Washington
2004
Honors: 
Tulane University, Honors in Biology
1987
National Research Service Award, NIH
2000
Keystone Symposium Scholarship, ‘From Stem Cells to Therapy’, E3
2003